netFormulary

North East and North Cumbria
ICS Formulary

8 Malignant disease and immunosuppression

08-01-05 Cetuximab

Cetuximab

Formulary

Approved for the first-line treatment of metastatic colorectal cancer in combination with FOLFOX in line with NICE (monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy - as per NICE).
NECDAG approved for K-RAS wild type metastatic colorectal cancer; second line use in combination with chemotherapy in patients that have progressed on previous chemotherapy; third line use as a single agent in patients who have failed oxaliplatin- and irinotecan based therapy and who are intolerant to irinotecan.
Approved for locally advanced squamous cell carcinoma of the head and neck in line with NICE.
Approved for previously untreated metastatic colorectal cancer in line with NICE.
Approved for the treatment of metastatic and/or recurrent squamous cell carcinoma of the head and neck (oral cavity only) in line with NICE and NHS England Commissioning Policy
Note: cetuximab is not approved in combination with platinum-based chemotherapy for recurrent and/or metastatic squamous cell cancer of the head and neck as per NICE.

Links